» Articles » PMID: 19118269

Association of IL-17RB Gene Polymorphism with Asthma

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2009 Jan 2
PMID 19118269
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Interleukin (IL)-17E is a member of the IL-17 family, which induces IL-4, IL-5, IL-13, and eotaxin in experimental animals via IL-17 receptor B (IL-17RB). The activation of IL-17RB amplifies allergic-type inflammatory responses by inducing Jun kinase (or JNK), p38 mitogen-activated protein kinase (or MAPK), and nuclear factor-kappaB.

Objectives: We examined the association of polymorphisms in the IL-17RB gene with asthma susceptibility and investigated the effects of those polymorphisms on the transcription of various IL-17RB isoforms.

Methods: In total, 954 asthmatic patients or 265 healthy control subjects were screened for polymorphisms in IL-17RB by single-base extension. The messenger RNA expression IL-17RB in B-cell lines derived from patients was also measured by reverse transcription-polymerase chain reaction.

Results: Direct sequencing of 24 unrelated Korean DNA samples revealed 18 genetic variants, including four insertion/deletions and 14 single-nucleotide polymorphisms (SNPs). Six of the SNPs (-1465G>A, +5661G>A, +6297T>C [Y123Y], +13797C>T, +18661C>T, and +18965G>A) were used to screen a larger group of subjects. Intronic polymorphism +5661G>A was significantly associated with the development of asthma (p = 0.001); moreover, a minor allele of IL-17RB +5661G>A appeared at a lower frequency in the asthmatic patients than in the healthy control subjects (0.13 vs 0.19, respectively). The IL-17RB messenger RNA expression in B cells homozygous for IL-17RB+ 5661GG was significantly higher than that in B cells homozygous for IL-17RB+5661AA (p = 0.002).

Conclusions: A rare allele of IL-17RB +5661G>A may have a protective role against the development of asthma via regulation at the level of transcription. The SNPs identified in this study may be used to develop markers to assess the risk of asthma.

Citing Articles

Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial.

Xu G, Paglialunga S, Qian X, Ding R, Webster K, van Haarst A Front Immunol. 2024; 15():1495540.

PMID: 39717777 PMC: 11663749. DOI: 10.3389/fimmu.2024.1495540.


Association between IL-10 (at position -592) and IL-4 (at position -589) genotype polymorphism with atopic and non-atopic asthma in children.

Razaghian A, Parvaneh N, Amirzargar A, Nirouei M, Gharagozlou M Am J Clin Exp Immunol. 2023; 12(5):98-106.

PMID: 38022870 PMC: 10658160.


In-silico identification and prioritization of therapeutic targets of asthma.

Mallick I, Panchal P, Kadam S, Mohite P, Scheele J, Seiz W Sci Rep. 2023; 13(1):15706.

PMID: 37735578 PMC: 10514284. DOI: 10.1038/s41598-023-42803-w.


Type 2 cytokine genes as allergic asthma risk factors after viral bronchiolitis in early childhood.

Dong Z, Myklebust A, Johnsen I, Jartti T, Dollner H, Risnes K Front Immunol. 2023; 13:1054119.

PMID: 36685501 PMC: 9852873. DOI: 10.3389/fimmu.2022.1054119.


Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.

Porsbjerg C, Sverrild A, Lloyd C, Menzies-Gow A, Bel E Eur Respir J. 2020; 56(5).

PMID: 32586879 PMC: 7676874. DOI: 10.1183/13993003.00260-2020.